Tech Daily Utah
SEE OTHER BRANDS

Fresh news on science and technology in Utah

Tech Daily Utah: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Daily Utah.

Press releases published on June 9, 2025

Secura Bio Announces First Patient Dosed in Phase 3 TERZO Study of COPIKTRA® (duvelisib) in Relapsed/Refractory Nodal T-follicular Helper Cell Lymphoma

Secura Bio Announces First Patient Dosed in Phase 3 TERZO Study of COPIKTRA® (duvelisib) in Relapsed/Refractory Nodal T-follicular Helper Cell Lymphoma

SUMMERLIN, Nev., June 09, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that the first patient has been dosed in its Phase 3 TERZO …

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a …

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of …

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host …

Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science

Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science

First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), …

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Preclinical data highlighted JADE101’s femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a differentiated pharmacokinetic and …

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the TransCon CNP-treated cohort, combination …

Keros Announces Return of $375 Million in Excess Capital to Stockholders

Keros Announces Return of $375 Million in Excess Capital to Stockholders

LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of …

Virtune AB (Publ) ("Virtune") has completed the monthly rebalancing for May 2025 of its Virtune Crypto Altcoin Index ETP

Virtune AB (Publ) ("Virtune") has completed the monthly rebalancing for May 2025 of its Virtune Crypto Altcoin Index ETP

Stockholm, 9th of June 2025 – Virtune AB (Publ) ("Virtune") today announces that it has completed the monthly rebalancing of the Virtune Crypto Altcoin Index ETP, listed on Nasdaq Stockholm and Nasdaq Helsinki (ISIN code SE0023260716). In addition to the …

Virtune AB (Publ) ("Virtune") har genomfört den månatliga rebalanseringen för maj 2025 av Virtune Crypto Altcoin Index ETP

Virtune AB (Publ) ("Virtune") har genomfört den månatliga rebalanseringen för maj 2025 av Virtune Crypto Altcoin Index ETP

Stockholm, 9 juni 2025 – Virtune meddelar idag att man har slutfört den månatliga rebalanseringen av Virtune Crypto Altcoin Index ETP, noterad på Nasdaq Stockholm och Nasdaq Helsinki (ISIN-kod SE0023260716). Utöver Virtune Crypto Altcoin Index ETP omfattar …

Quid Miner's new application dominated the hot search list as soon as it was launched

Quid Miner's new application dominated the hot search list as soon as it was launched

Houston, TX, June 09, 2025 (GLOBE NEWSWIRE) -- Quid Miner recently launched a new mobile app: allowing users to mine easily anytime and anywhere. As a green cloud mining platform established legally and compliantly in the UK. It provides mining services …

$ZEUS Announces the Next Era: Trademark Secured, Artist Doxxed, Legacy Unleashed

$ZEUS Announces the Next Era: Trademark Secured, Artist Doxxed, Legacy Unleashed

Panama City, Panama, June 09, 2025 (GLOBE NEWSWIRE) -- In a sea of derivatives and half-baked memes, $ZEUS is setting a new standard, not just for meme coins, but for storytelling, ownership, and community-driven culture on-chain. Over the past 48 hours, $ …

Red Cat Supports Executive Orders to Strengthen U.S. Drone Manufacturing and National Security

Red Cat Supports Executive Orders to Strengthen U.S. Drone Manufacturing and National Security

SAN JUAN, Puerto Rico, June 09, 2025 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (Nasdaq: RCAT), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, today issued a statement of support …

Portage Biotech and Compedica Stock-for-Stock Exchange

Portage Biotech and Compedica Stock-for-Stock Exchange

DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”) announce that on June 5, 2025 Portage and Compedica Holdings …

YXT.com's AI Learning Platform Deployed by Siemens for Digital Workforce Transformation

YXT.com's AI Learning Platform Deployed by Siemens for Digital Workforce Transformation

SUZHOU, China, June 09, 2025 (GLOBE NEWSWIRE) -- YXT.com Group Holding Limited (NASDAQ: YXT) (“YXT.com” or the “Company”), a provider of AI-enabled enterprise productivity solutions, today announced that the global industrial technology leader Siemens has …

WAYS.cash Wins Grand Champion Title at Solrift Hackathon for Privacy-Focused Payment Toolkit

WAYS.cash Wins Grand Champion Title at Solrift Hackathon for Privacy-Focused Payment Toolkit

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- WAYS.cash, the first self-custodial stealth-address payment toolkit on Solana, has been named Grand Champion of the “A Breach in the Norm” hackathon hosted by Solrift. The win earned the New York–based project a …

CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform

CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform

Lehi, Utah, June 09, 2025 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that it will expand its preclinical program to …

AB Science announces EMA approval of Masivet shelf-life extension to 4 years

AB Science announces EMA approval of Masivet shelf-life extension to 4 years

PRESS RELEASE AB SCIENCE ANNOUNCES EMA APPROVAL OF MASIVET® SHELF-LIFE EXTENSION TO 4 YEARS Paris, June 9, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Medicine Agency (EMA) has approved the extension of the …

AB Science annonce l’approbation par l’EMA de la prolongation de la durée de conservation de Masivet à 4 ans

AB Science annonce l’approbation par l’EMA de la prolongation de la durée de conservation de Masivet à 4 ans

COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE L'APPROBATION PAR L'EMA DE LA PROLONGATION DE LA DURÉE DE CONSERVATION DE MASIVET® À 4 ANS Paris, 9 juin 2025, 8h AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd'hui que l'Agence européenne des …

UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING

UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING

UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING Nantes, June 9th, 2025, 8 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) informs its shareholders and the market of the update on the terms of the Combined General Meeting scheduled …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service